![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 22, 2020 7:56:18 AM
Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity
BY PR Newswire
— 7:45 AM ET 12/22/2020
PHOENIX, Dec. 22, 2020 /PRNewswire/ -- Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today data identifying one of the primary mechanisms of action of its ImmCelz® product in the treatment of stroke. The Company reported that animals having previously been treated with ImmCelz® have an increase in what is called "endogenous neurogenesis". This process allows for certain parts of the brain to heal themselves more effectively after injury, for example, such as in stroke. The stimulation of endogenous neurogenesis was approximately 85% higher than in animals treatment with a popular type of stem cell termed mesenchymal stem cells. Additionally, the Company reported that depletion of animals of T regulatory cells resulted in suppression of endogenous neurogenesis.
Creative Medical Technology Holdings, Inc. Logo (PRNewsfoto/Creative Medical Technology Hol)
"These findings are continuation of work initiated years ago in which we sought to dissect not only immunological mechanisms of ImmCelz® activity, but also other physiological systems, including the nervous system." Said Dr. Amit Patel, Board Member of the Company. "The elucidation of a mechanism of action makes ImmCelz® an increasingly viable candidate for FDA IND application and initiation of clinical trials."
In contrast to stem cell based approaches, ImmCelz® is an immunotherapy product in which stem cells are used to "educate" immune cells to endow them with regenerative activity.
The Company believes that "educated" immune cells may be superior to stem cells because of their: a) ability to replicate and form "memory" cells; b) substantially smaller size, which allows for superior biodistribution than stem cells; and c) adeptness at surviving in conditions such as hypoxia or acidosis, which would inactivate stem cells.
"I would like to thank my colleagues who have steadily worked tirelessly on this project for years. The possibility of immune cells being coaxed into possessing regenerative activity is quite a revolutionary concept, which thanks to these recent experiments appears to be becoming a reality." Said Thomas E Ichim, Ph.D, Chief Scientific Officer and co-inventor of ImmCelz®.
"Stroke represents a significant unmet medical need for which numerous other approaches have failed." Said Timothy Warbington, President and CEO of the Company. "By understanding the biological switches that ImmCelz® activates to reduce stroke in animals, we believe that our path through the FDA will be less challenging, as well as our road to eventual commercialization."
About Creative Medical Technology Holdings ( CELZ
Loading...
Loading...
)
Creative Medical Technology Holdings, Inc. ( CELZ
Loading...
Loading...
) is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com.
Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. ( CELZ
Loading...
Loading...
) with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
Timothy Warbington, CEO
CEO@CreativeMedicalHealth.com
Creativemedicaltechnology.com
www.StemSpine.com
www.Caverstem.com
www.Femcelz.com
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/creative-medical-technology-holdings-identifies-mechanism-of-action-of-immcelz-stroke-regenerative-activity-301197267.html
Recent CELZ News
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM